Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial
Keloid, Stem Cell
About this trial
This is an interventional treatment trial for Keloid focused on measuring Keloid therapy, mesenchymal stem cells, keloid volume, POSAS
Eligibility Criteria
Inclusion Criteria: The patient has keloids with a length of 2-10 cm and a thickness of 3-5 mm located on the chest, back, abdomen and extremities Patients aged 18 - 55 years Post-surgery patients more than 3 months that cause keloids The patient is willing to fill in the informed consent form Exclusion Criteria: Patients with hypertrophic scars History of kidney failure Hypertension Pregnant and breastfeeding History of blood disorders History of tumor or malignancy Get other keloid therapy outside of the research procedure
Sites / Locations
- RSPAD Gatot Soebroto
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
umbilical cord-derived mesenchymal stem cells (UC-MSC)
umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)
triamcinolone acetonide
UC-MSC was collected in 50 mL of transport medium, which contained alpha minimal essential medium (αMEM [GIBCO 12000-0221]), penicillin/streptomycin (final concentration 300u/mL [GIBCO 15140-122]) and amphotericin B (final concentration 7500ng /mL [JR Scientific 50701]), and processed in less than 8 hours after collection. Group 1 was given UC-MSC 2 million cells/mL/cm3
group 2 was given UC-CM 1 mL/cm3
group 3 was given TA 40 mg/mL/cm3